文献速递白血病

双受体T细胞平台通过抗体-T细胞受体与共刺激受体实现对急性髓系白血病的特异性和效力

A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
PubMed 文献 · Blood · 2024-01-01

该研究构建了靶向WT1和CD33的双受体T细胞平台AbTCR-CSR,其中AbTCR包含针对WT1 RMFPNAPYL肽/HLA-A2复合物的TCR模拟单克隆抗体ESK2,CSR包含靶向CD33的单链可变区与截短的CD28共刺激片段。该平台对急性髓系白血病细胞产生特异性细胞毒性,同时不损伤包括CD33+髓单核正常细胞在内的健康造血细胞。

要点

  • AbTCR-CSR平台同时靶向WT1和CD33两个抗原,两者在急性髓系白血病细胞上共表达而正常细胞不共表达。
  • AbTCR使用新开发的TCR模拟单克隆抗体ESK2识别WT1 RMFPNAPYL肽/HLA-A2复合物。
  • CSR使用靶向CD33的单链可变区连接截短的CD28共刺激片段。

核心结论

  • AbTCR-CSR平台通过抗体-T细胞受体CAR与共刺激受体的组合,可能是降低毒性、提高特异性和改善急性髓系白血病过继T细胞治疗临床结局的有效策略。

研究设计与样本

  • 研究构建了靶向WT1和CD33的双受体T细胞平台AbTCR-CSR,并进行概念验证。

主要发现

  • AbTCR包含新开发的针对WT1 RMFPNAPYL肽/HLA-A2复合物的TCR模拟单克隆抗体ESK2。
  • CSR包含靶向CD33的单链可变区与截短的CD28共刺激片段。
  • 该平台对急性髓系白血病细胞产生特异性T细胞细胞毒性,同时不损伤包括CD33+髓单核正常细胞在内的健康造血细胞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T-cell (CAR T) therapy has produced remarkable clinical responses in B-cell neoplasms. However, many challenges limit this class of agents for the treatment of other cancer types, in particular the lack of tumor-selective antigens for solid tumors and other hematological malignancies, such as acute myeloid leukemia (AML), which may be addressed without significant risk of severe toxicities while providing sufficient abundance for efficient tumor suppression. One approach to overcome this hurdle is dual targeting by an antibody-T-cell receptor (AbTCR) and a chimeric costimulatory signaling receptor (CSR) to 2 different antigens, in which both antigens are found together on the cancer cells but not together on normal cells. To explore this proof of concept in AML, we engineered a new T-cell format targeting Wilms tumor 1 protein (WT1) and CD33; both are highly expressed on most AML cells. Using an AbTCR comprising a newly developed TCR-mimic monoclonal antibody against the WT1 RMFPNAPYL (RMF) epitope/HLA-A2 complex, ESK2, and a secondary CSR comprising a single-chain variable fragment directed to CD33 linked to a truncated CD28 costimulatory fragment, this unique platform confers specific T-cell cytotoxicity to the AML cells while sparing healthy hematopoietic cells, including CD33+ myelomonocytic normal cells. These data suggest that this new platform, named AbTCR-CSR, through the combination of a AbTCR CAR and CSR could be an effective strategy to reduce toxicity and improve specificity and clinical outcomes in adoptive T-cell therapy in AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Dao T, Xiong G, Mun SS, et al. A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML. Blood. 2024. PMID: 38048594. doi:10.1182/blood.2023021054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。